25 XP   0   0   10

Noxopharm Ltd
Buy, Hold or Sell?

Let's analyse Noxopharm together

PenkeI guess you are interested in Noxopharm Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Noxopharm Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Noxopharm Ltd

I send you an email if I find something interesting about Noxopharm Ltd.

Quick analysis of Noxopharm (30 sec.)










What can you expect buying and holding a share of Noxopharm? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
25.0%

What is your share worth?

Current worth
A$0.03
Expected worth in 1 year
A$-0.17
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-0.21
Return On Investment
-307.3%

For what price can you sell your share?

Current Price per Share
A$0.07
Expected price per share
A$0.051 - A$0.074
How sure are you?
50%

1. Valuation of Noxopharm (5 min.)




Live pricePrice per Share (EOD)

A$0.07

Intrinsic Value Per Share

A$-0.32 - A$-0.25

Total Value Per Share

A$-0.29 - A$-0.22

2. Growth of Noxopharm (5 min.)




Is Noxopharm growing?

Current yearPrevious yearGrowGrow %
How rich?$5.9m$15.7m-$9.8m-165.8%

How much money is Noxopharm making?

Current yearPrevious yearGrowGrow %
Making money-$9.8m-$12.1m$2.3m24.0%
Net Profit Margin-250.5%-343.9%--

How much money comes from the company's main activities?

3. Financial Health of Noxopharm (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#749 / 1031

Most Revenue
#376 / 1031

Most Profit
#585 / 1031

Most Efficient
#688 / 1031

What can you expect buying and holding a share of Noxopharm? (5 min.)

Welcome investor! Noxopharm's management wants to use your money to grow the business. In return you get a share of Noxopharm.

What can you expect buying and holding a share of Noxopharm?

First you should know what it really means to hold a share of Noxopharm. And how you can make/lose money.

Speculation

The Price per Share of Noxopharm is A$0.067. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Noxopharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Noxopharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.03. Based on the TTM, the Book Value Change Per Share is A$-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Noxopharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.03-50.2%-0.03-50.2%-0.04-62.2%-0.02-36.4%-0.02-31.9%
Usd Book Value Change Per Share-0.03-50.1%-0.03-50.1%-0.04-55.5%0.00-0.7%0.003.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.0118.2%0.0111.4%
Usd Total Gains Per Share-0.03-50.1%-0.03-50.1%-0.04-55.5%0.0117.5%0.0115.2%
Usd Price Per Share0.03-0.03-0.13-0.20-0.20-
Price to Earnings Ratio-0.83--0.83--3.05--42.73--32.30-
Price-to-Total Gains Ratio-0.84--0.84--3.42--1.91--2.43-
Price to Book Ratio1.38-1.38-2.36--16.72--2.85-
Price-to-Total Gains Ratio-0.84--0.84--3.42--1.91--2.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0437041
Number of shares22881
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.030.00
Usd Total Gains Per Share-0.030.01
Gains per Quarter (22881 shares)-768.37267.99
Gains per Year (22881 shares)-3,073.471,071.95
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-3073-30831116-441062
20-6147-61562232-882134
30-9220-92293348-1323206
40-12294-123024463-1764278
50-15367-153755579-2205350
60-18441-184486695-2636422
70-21514-215217811-3077494
80-24588-245948927-3518566
90-27661-2766710043-3959638
100-30735-3074011159-43910710

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.08.00.00.0%0.08.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.04.00.050.0%4.04.00.050.0%
Dividend per Share0.00.01.00.0%1.00.02.033.3%2.00.03.040.0%2.00.06.025.0%2.00.06.025.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.04.00.050.0%4.04.00.050.0%

Fundamentals of Noxopharm

About Noxopharm Ltd

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Fundamental data was last updated by Penke on 2024-03-20 07:42:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Noxopharm Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Noxopharm earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Noxopharm to the Biotechnology industry mean.
  • A Net Profit Margin of -250.5% means that $-2.51 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Noxopharm Ltd:

  • The MRQ is -250.5%. The company is making a huge loss. -2
  • The TTM is -250.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-250.5%TTM-250.5%0.0%
TTM-250.5%YOY-343.9%+93.3%
TTM-250.5%5Y-209.9%-40.6%
5Y-209.9%10Y-25,030.8%+24,820.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-250.5%-171.8%-78.7%
TTM-250.5%-205.8%-44.7%
YOY-343.9%-262.1%-81.8%
5Y-209.9%-455.6%+245.7%
10Y-25,030.8%-589.0%-24,441.8%
1.1.2. Return on Assets

Shows how efficient Noxopharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Noxopharm to the Biotechnology industry mean.
  • -148.7% Return on Assets means that Noxopharm generated $-1.49 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Noxopharm Ltd:

  • The MRQ is -148.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -148.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-148.7%TTM-148.7%0.0%
TTM-148.7%YOY-70.2%-78.5%
TTM-148.7%5Y-100.1%-48.5%
5Y-100.1%10Y-93.2%-7.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-148.7%-12.5%-136.2%
TTM-148.7%-12.2%-136.5%
YOY-70.2%-11.2%-59.0%
5Y-100.1%-13.4%-86.7%
10Y-93.2%-14.7%-78.5%
1.1.3. Return on Equity

Shows how efficient Noxopharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Noxopharm to the Biotechnology industry mean.
  • -165.9% Return on Equity means Noxopharm generated $-1.66 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Noxopharm Ltd:

  • The MRQ is -165.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -165.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-165.9%TTM-165.9%0.0%
TTM-165.9%YOY-77.4%-88.5%
TTM-165.9%5Y-53.7%-112.3%
5Y-53.7%10Y-73.0%+19.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-165.9%-15.8%-150.1%
TTM-165.9%-15.7%-150.2%
YOY-77.4%-13.9%-63.5%
5Y-53.7%-18.3%-35.4%
10Y-73.0%-19.2%-53.8%

1.2. Operating Efficiency of Noxopharm Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Noxopharm is operating .

  • Measures how much profit Noxopharm makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Noxopharm to the Biotechnology industry mean.
  • An Operating Margin of -276.1% means the company generated $-2.76  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Noxopharm Ltd:

  • The MRQ is -276.1%. The company is operating very inefficient. -2
  • The TTM is -276.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-276.1%TTM-276.1%0.0%
TTM-276.1%YOY-280.1%+4.0%
TTM-276.1%5Y-263.4%-12.7%
5Y-263.4%10Y-37,222.5%+36,959.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-276.1%-299.1%+23.0%
TTM-276.1%-210.1%-66.0%
YOY-280.1%-279.7%-0.4%
5Y-263.4%-459.9%+196.5%
10Y-37,222.5%-596.9%-36,625.6%
1.2.2. Operating Ratio

Measures how efficient Noxopharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.76 means that the operating costs are $2.76 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Noxopharm Ltd:

  • The MRQ is 2.761. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.761. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.761TTM2.7610.000
TTM2.761YOY2.801-0.040
TTM2.7615Y2.825-0.064
5Y2.82510Y371.377-368.552
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7612.861-0.100
TTM2.7613.193-0.432
YOY2.8013.615-0.814
5Y2.8255.560-2.735
10Y371.3777.396+363.981

1.3. Liquidity of Noxopharm Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Noxopharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.52 means the company has $9.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Noxopharm Ltd:

  • The MRQ is 9.519. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.519. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.519TTM9.5190.000
TTM9.519YOY9.134+0.385
TTM9.5195Y5.204+4.316
5Y5.20410Y8.666-3.463
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5193.986+5.533
TTM9.5194.440+5.079
YOY9.1345.552+3.582
5Y5.2046.158-0.954
10Y8.6666.492+2.174
1.3.2. Quick Ratio

Measures if Noxopharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Noxopharm to the Biotechnology industry mean.
  • A Quick Ratio of 9.45 means the company can pay off $9.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Noxopharm Ltd:

  • The MRQ is 9.451. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.451. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.451TTM9.4510.000
TTM9.451YOY8.428+1.023
TTM9.4515Y4.992+4.459
5Y4.99210Y8.369-3.378
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.4513.638+5.813
TTM9.4514.168+5.283
YOY8.4285.515+2.913
5Y4.9926.012-1.020
10Y8.3696.209+2.160

1.4. Solvency of Noxopharm Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Noxopharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Noxopharm to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Noxopharm assets are financed with 10.4% credit (debt) and the remaining percentage (100% - 10.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Noxopharm Ltd:

  • The MRQ is 0.104. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.104. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.104TTM0.1040.000
TTM0.104YOY0.093+0.011
TTM0.1045Y0.408-0.304
5Y0.40810Y0.314+0.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1040.335-0.231
TTM0.1040.330-0.226
YOY0.0930.267-0.174
5Y0.4080.367+0.041
10Y0.3140.378-0.064
1.4.2. Debt to Equity Ratio

Measures if Noxopharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Noxopharm to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.6% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Noxopharm Ltd:

  • The MRQ is 0.116. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.116. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.116TTM0.1160.000
TTM0.116YOY0.103+0.014
TTM0.1165Y0.190-0.074
5Y0.19010Y0.197-0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1160.376-0.260
TTM0.1160.398-0.282
YOY0.1030.334-0.231
5Y0.1900.429-0.239
10Y0.1970.476-0.279

2. Market Valuation of Noxopharm Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Noxopharm generates.

  • Above 15 is considered overpriced but always compare Noxopharm to the Biotechnology industry mean.
  • A PE ratio of -0.83 means the investor is paying $-0.83 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Noxopharm Ltd:

  • The EOD is -1.300. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.835. Based on the earnings, the company is expensive. -2
  • The TTM is -0.835. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.300MRQ-0.835-0.466
MRQ-0.835TTM-0.8350.000
TTM-0.835YOY-3.053+2.218
TTM-0.8355Y-42.728+41.893
5Y-42.72810Y-32.301-10.427
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.300-2.643+1.343
MRQ-0.835-2.418+1.583
TTM-0.835-2.742+1.907
YOY-3.053-4.123+1.070
5Y-42.728-6.257-36.471
10Y-32.301-6.478-25.823
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Noxopharm Ltd:

  • The EOD is -1.789. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.148. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.148. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.789MRQ-1.148-0.641
MRQ-1.148TTM-1.1480.000
TTM-1.148YOY-4.149+3.001
TTM-1.1485Y-4,346.127+4,344.979
5Y-4,346.12710Y-2,723.152-1,622.975
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.789-3.244+1.455
MRQ-1.148-2.939+1.791
TTM-1.148-3.478+2.330
YOY-4.149-5.592+1.443
5Y-4,346.127-8.473-4,337.654
10Y-2,723.152-8.881-2,714.271
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Noxopharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.38 means the investor is paying $1.38 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Noxopharm Ltd:

  • The EOD is 2.158. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.385. Based on the equity, the company is underpriced. +1
  • The TTM is 1.385. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.158MRQ1.385+0.773
MRQ1.385TTM1.3850.000
TTM1.385YOY2.363-0.978
TTM1.3855Y-16.717+18.102
5Y-16.71710Y-2.849-13.868
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1582.124+0.034
MRQ1.3852.041-0.656
TTM1.3852.118-0.733
YOY2.3632.915-0.552
5Y-16.7173.682-20.399
10Y-2.8494.114-6.963
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Noxopharm Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Noxopharm Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.051-0.0510%-0.057+11%-0.001-99%0.004-1427%
Book Value Per Share--0.0310.0310%0.083-62%0.058-47%0.044-30%
Current Ratio--9.5199.5190%9.134+4%5.204+83%8.666+10%
Debt To Asset Ratio--0.1040.1040%0.093+12%0.408-74%0.314-67%
Debt To Equity Ratio--0.1160.1160%0.103+13%0.190-39%0.197-41%
Dividend Per Share----0%-0%0.019-100%0.012-100%
Eps---0.052-0.0520%-0.064+24%-0.037-28%-0.033-36%
Free Cash Flow Per Share---0.037-0.0370%-0.047+25%-0.031-18%-0.025-34%
Free Cash Flow To Equity Per Share---0.038-0.0380%-0.044+15%0.000-99%0.005-823%
Gross Profit Margin--1.0131.0130%1.006+1%1.103-8%1.071-5%
Intrinsic Value_10Y_max---0.251--------
Intrinsic Value_10Y_min---0.321--------
Intrinsic Value_1Y_max---0.029--------
Intrinsic Value_1Y_min---0.037--------
Intrinsic Value_3Y_max---0.085--------
Intrinsic Value_3Y_min---0.108--------
Intrinsic Value_5Y_max---0.137--------
Intrinsic Value_5Y_min---0.174--------
Market Cap19579947.072+36%12566234.68812566234.6880%56986413.120-78%89015699.674-86%91251320.496-86%
Net Profit Margin---2.505-2.5050%-3.439+37%-2.099-16%-250.308+9892%
Operating Margin---2.761-2.7610%-2.801+1%-2.634-5%-372.225+13381%
Operating Ratio--2.7612.7610%2.801-1%2.825-2%371.377-99%
Pb Ratio2.158+36%1.3851.3850%2.363-41%-16.717+1307%-2.849+306%
Pe Ratio-1.300-56%-0.835-0.8350%-3.053+266%-42.728+5019%-32.301+3770%
Price Per Share0.067+36%0.0430.0430%0.195-78%0.305-86%0.312-86%
Price To Free Cash Flow Ratio-1.789-56%-1.148-1.1480%-4.149+261%-4346.127+378488%-2723.152+237112%
Price To Total Gains Ratio-1.301-56%-0.835-0.8350%-3.421+310%-1.906+128%-2.426+190%
Quick Ratio--9.4519.4510%8.428+12%4.992+89%8.369+13%
Return On Assets---1.487-1.4870%-0.702-53%-1.001-33%-0.932-37%
Return On Equity---1.659-1.6590%-0.774-53%-0.537-68%-0.730-56%
Total Gains Per Share---0.051-0.0510%-0.057+11%0.018-387%0.016-431%
Usd Book Value--5918488.1505918488.1500%15732134.871-62%11139962.310-47%8475933.364-30%
Usd Book Value Change Per Share---0.034-0.0340%-0.037+11%0.000-99%0.003-1427%
Usd Book Value Per Share--0.0200.0200%0.054-62%0.038-47%0.029-30%
Usd Dividend Per Share----0%-0%0.012-100%0.008-100%
Usd Eps---0.034-0.0340%-0.042+24%-0.024-28%-0.021-36%
Usd Free Cash Flow---7140300.844-7140300.8440%-8958379.662+25%-5828648.567-18%-4699174.418-34%
Usd Free Cash Flow Per Share---0.024-0.0240%-0.031+25%-0.020-18%-0.016-34%
Usd Free Cash Flow To Equity Per Share---0.025-0.0250%-0.028+15%0.000-99%0.003-823%
Usd Market Cap12771999.475+36%8196954.8878196954.8870%37172237.278-78%58064940.897-86%59523236.360-86%
Usd Price Per Share0.044+36%0.0280.0280%0.127-78%0.199-86%0.204-86%
Usd Profit---9821272.108-9821272.1080%-12176360.163+24%-7118525.374-28%-6245686.396-36%
Usd Revenue--3920379.0983920379.0980%3541105.786+11%3818120.245+3%2482009.409+58%
Usd Total Gains Per Share---0.034-0.0340%-0.037+11%0.012-387%0.010-431%
 EOD+5 -3MRQTTM+0 -0YOY+22 -125Y+8 -2810Y+10 -26

4.2. Fundamental Score

Let's check the fundamental score of Noxopharm Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.300
Price to Book Ratio (EOD)Between0-12.158
Net Profit Margin (MRQ)Greater than0-2.505
Operating Margin (MRQ)Greater than0-2.761
Quick Ratio (MRQ)Greater than19.451
Current Ratio (MRQ)Greater than19.519
Debt to Asset Ratio (MRQ)Less than10.104
Debt to Equity Ratio (MRQ)Less than10.116
Return on Equity (MRQ)Greater than0.15-1.659
Return on Assets (MRQ)Greater than0.05-1.487
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Noxopharm Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.865
Ma 20Greater thanMa 500.070
Ma 50Greater thanMa 1000.068
Ma 100Greater thanMa 2000.082
OpenGreater thanClose0.065
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Net Interest Income  -464-2,991-3,4561,409-2,0472,016-307242



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets10,128
Total Liabilities1,055
Total Stockholder Equity9,073
 As reported
Total Liabilities 1,055
Total Stockholder Equity+ 9,073
Total Assets = 10,128

Assets

Total Assets10,128
Total Current Assets9,159
Long-term Assets969
Total Current Assets
Cash And Cash Equivalents 3,009
Net Receivables 6,085
Other Current Assets 66
Total Current Assets  (as reported)9,159
Total Current Assets  (calculated)9,159
+/-0
Long-term Assets
Property Plant Equipment 7
Long Term Investments 962
Long-term Assets  (as reported)969
Long-term Assets  (calculated)969
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities962
Long-term Liabilities93
Total Stockholder Equity9,073
Total Current Liabilities
Accounts payable 448
Other Current Liabilities 514
Total Current Liabilities  (as reported)962
Total Current Liabilities  (calculated)962
+/-0
Long-term Liabilities
Other Liabilities 93
Long-term Liabilities  (as reported)93
Long-term Liabilities  (calculated)93
+/- 0
Total Stockholder Equity
Common Stock74,636
Retained Earnings -72,061
Other Stockholders Equity 6,498
Total Stockholder Equity (as reported)9,073
Total Stockholder Equity (calculated)9,073
+/-0
Other
Capital Stock74,636
Cash and Short Term Investments 3,009
Common Stock Shares Outstanding 292,238
Liabilities and Stockholders Equity 10,128
Net Debt -3,009
Net Invested Capital 9,073
Net Tangible Assets 9,073
Net Working Capital 8,197
Property Plant and Equipment Gross 7



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-30
> Total Assets 
6,208
2,829
14,549
4,300
20,067
47,854
26,594
10,128
10,12826,59447,85420,0674,30014,5492,8296,208
   > Total Current Assets 
6,191
2,567
14,076
3,888
12,329
32,974
20,833
9,159
9,15920,83332,97412,3293,88814,0762,5676,191
       Cash And Cash Equivalents 
6,178
2,458
12,614
2,910
7,100
26,796
14,011
3,009
3,00914,01126,7967,1002,91012,6142,4586,178
       Short-term Investments 
10
0
0
0
0
0
0
0
000000010
       Net Receivables 
6
63
123
160
4,647
5,799
5,213
6,085
6,0855,2135,7994,647160123636
       Inventory 
0
0
1,269
121
519
312
1,146
0
01,1463125191211,26900
   > Long-term Assets 
17
261
474
413
7,738
14,880
5,760
969
9695,76014,8807,73841347426117
       Property Plant Equipment 
5
64
318
257
851
484
222
7
7222484851257318645
       Long Term Investments 
0
0
0
0
6,539
14,272
5,415
962
9625,41514,2726,5390000
       Intangible Assets 
0
1
37
37
0
0
0
0
0000373710
       Other Assets 
0
196
119
119
0
0
0
0
00001191191960
> Total Liabilities 
262
361
4,401
5,751
7,194
7,077
2,476
1,055
1,0552,4767,0777,1945,7514,401361262
   > Total Current Liabilities 
262
361
1,122
5,751
6,686
6,807
2,281
962
9622,2816,8076,6865,7511,122361262
       Short-term Debt 
0
0
3,279
3,930
4,587
232
161
0
01612324,5873,9303,27900
       Short Long Term Debt 
0
0
3,279
3,930
4,342
0
0
0
0004,3423,9303,27900
       Accounts payable 
283
291
887
1,487
1,787
6,130
810
448
4488106,1301,7871,487887291283
       Other Current Liabilities 
9
70
235
333
312
445
1,310
514
5141,310445312333235709
   > Long-term Liabilities 
0
0
3,279
5,417
509
270
195
93
931952705095,4173,27900
       Long term Debt Total 
0
0
3,279
0
413
118
0
0
0011841303,27900
       Other Liabilities 
0
0
0
0
95
152
195
93
93195152950000
> Total Stockholder Equity
5,946
2,468
10,148
-101
12,873
40,776
24,118
9,073
9,07324,11840,77612,873-10110,1482,4685,946
   Common Stock
6,352
6,218
28,449
28,701
41,631
72,623
74,636
74,636
74,63674,63672,62341,63128,70128,4496,2186,352
   Retained Earnings -72,061-58,803-40,333-31,466-33,257-22,034-3,751-600
   Accumulated Other Comprehensive Income 
194
-22
3,733
4,455
2,708
8,487
8,285
6,498
6,4988,2858,4872,7084,4553,733-22194
   Capital Surplus 00000000
   Treasury Stock00000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue6,010
Cost of Revenue-155
Gross Profit5,8565,856
 
Operating Income (+$)
Gross Profit5,856
Operating Expense-16,441
Operating Income-16,595-10,585
 
Operating Expense (+$)
Research Development10,647
Selling General Administrative1,477
Selling And Marketing Expenses192
Operating Expense16,44112,316
 
Net Interest Income (+$)
Interest Income4,494
Interest Expense-41
Other Finance Cost-4,411
Net Interest Income42
 
Pretax Income (+$)
Operating Income-16,595
Net Interest Income42
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-21,041-12,149
EBIT - interestExpense = -16,636
-21,041
-15,015
Interest Expense41
Earnings Before Interest and Taxes (EBIT)-16,595-21,000
Earnings Before Interest and Taxes (EBITDA)-16,441
 
After tax Income (+$)
Income Before Tax-21,041
Tax Provision-0
Net Income From Continuing Ops-15,056-21,041
Net Income-15,056
Net Income Applicable To Common Shares-15,056
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,595
Total Other Income/Expenses Net-4,446-42
 

Technical Analysis of Noxopharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Noxopharm. The general trend of Noxopharm is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Noxopharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Noxopharm Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.065 < 0.065 < 0.074.

The bearish price targets are: 0.059 > 0.055 > 0.051.

Tweet this
Noxopharm Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Noxopharm Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Noxopharm Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Noxopharm Ltd. The current macd is -0.0010884.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Noxopharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Noxopharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Noxopharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Noxopharm Ltd Daily Moving Average Convergence/Divergence (MACD) ChartNoxopharm Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Noxopharm Ltd. The current adx is 16.14.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Noxopharm shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Noxopharm Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Noxopharm Ltd. The current sar is 0.08795365.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Noxopharm Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Noxopharm Ltd. The current rsi is 47.86. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Noxopharm Ltd Daily Relative Strength Index (RSI) ChartNoxopharm Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Noxopharm Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Noxopharm price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Noxopharm Ltd Daily Stochastic Oscillator ChartNoxopharm Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Noxopharm Ltd. The current cci is -85.47008547.

Noxopharm Ltd Daily Commodity Channel Index (CCI) ChartNoxopharm Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Noxopharm Ltd. The current cmo is -4.97600843.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Noxopharm Ltd Daily Chande Momentum Oscillator (CMO) ChartNoxopharm Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Noxopharm Ltd. The current willr is -53.84615385.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Noxopharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Noxopharm Ltd Daily Williams %R ChartNoxopharm Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Noxopharm Ltd.

Noxopharm Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Noxopharm Ltd. The current atr is 0.00537814.

Noxopharm Ltd Daily Average True Range (ATR) ChartNoxopharm Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Noxopharm Ltd. The current obv is 4,235,508.

Noxopharm Ltd Daily On-Balance Volume (OBV) ChartNoxopharm Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Noxopharm Ltd. The current mfi is 41.88.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Noxopharm Ltd Daily Money Flow Index (MFI) ChartNoxopharm Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Noxopharm Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Noxopharm Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Noxopharm Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.865
Ma 20Greater thanMa 500.070
Ma 50Greater thanMa 1000.068
Ma 100Greater thanMa 2000.082
OpenGreater thanClose0.065
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Noxopharm with someone you think should read this too:
  • Are you bullish or bearish on Noxopharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Noxopharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Noxopharm Ltd

I send you an email if I find something interesting about Noxopharm Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Noxopharm Ltd.

Receive notifications about Noxopharm Ltd in your mailbox!